Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PF-06821497, Mervometostat (PF-06821497), Mervometostat
Mevrometostat · 1 trial · 4 indications
rPFS is defined as the time from randomization until PD based on BICR assessment per RECIST v1.1 (soft tissue disease) and PCWG3 (bone disease), or death due to any cause, whichever occurs first.
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | Participants will receive mevrometostat/PF-06821497 (875 mg) BID (twice daily) + enzalutamide 160 mg QD (once daily) |
| Arm B | ACTIVE_COMPARATOR | Participants will receive Placebo BID (twice daily) + enzalutamide 160 mg QD (once daily) |
| Name | Type | Description |
|---|---|---|
| Mevrometostat | DRUG | Oral continuous |
| Placebo | DRUG | Oral continuous |
| Enzalutamide | DRUG | Oral continuous |
Inclusion Criteria * Male participants aged ≥18 years (or the minimum age of consent in accordance with local regulations) at screening. * Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features. * Metastatic prostate cancer documented by positive bone s...
Mervometostat is an investigational small molecule being developed by Pfizer for metastatic castration-resistant prostate cancer (mCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). It is also being studied in healthy participants to understand how the drug is processed by the body.
Mervometostat is a small molecule enzyme inhibitor, classified under the -stat (enzyme) target class. It is being studied to treat prostate cancer by targeting specific enzymes involved in cancer growth, though the exact molecular target is not disclosed in the available information.
Mervometostat is developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is also known by the code name PF-06821497.
Mervometostat is in Phase 1 clinical development for metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. It is also being studied in healthy participants. The drug is investigational and has not been approved by regulatory authorities.
Mervometostat is being studied in several clinical trials. NCT03460977 is a Phase 1 trial in mCRPC, small cell lung cancer, and follicular lymphoma. NCT06392230 is a completed Phase 1 trial in healthy participants. NCT06629779 is a Phase 3 trial in mCRPC, and NCT07028853 is a Phase 3 trial in mCSPC.
Yes, Mervometostat is also known as PF-06821497. The drug is referred to by both names in clinical trial registries and scientific literature, with PF-06821497 being the code name used during early development.